Meeting
2014 Genitourinary Cancers Symposium
Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.
Authors
Bobby Chi-Hung Liaw
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
Bobby Chi-Hung Liaw , Sonia Maria Seng , Matt D. Galsky , Che-Kai Tsao , Phillip G. Febbo , William K. Oh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01289067
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 170)
DOI
10.1200/jco.2014.32.4_suppl.170
Abstract #
170
Poster Bd #
K13
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Association of health-related quality of life (HRQOL) variations with biological biomarkers for patients with metastatic castrate-resistant prostate cancer (MCRPC) treated by abiraterone/prednisone combination or prednisone.
First Author: Morgan Goujon
Poster
2012 Genitourinary Cancers Symposium
Safety and efficacy of maintenance therapy (MT) with a nonspecific cytochrome-P 17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castratation-resistant prostate cancer (mCRPC) patients.
First Author: Ignacio Gil-Bazo
Poster
2023 ASCO Annual Meeting
A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
First Author: Daniel J. George
Poster
2020 ASCO Virtual Scientific Program
Radiographic paradoxical response in patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with second-generation hormone therapy (second-HT).
First Author: Jamal Alamiri